Status:
COMPLETED
Imaging Biomarkers for TMS Treatment of Depression
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Neuronetics
Conditions:
Depression
Eligibility:
All Genders
22-65 years
Phase:
NA
Brief Summary
The purpose of this research is to learn more about how rTMS works to reduce the symptoms of depression. This information can be used to improve the effectiveness of the treatment. The study will use ...
Eligibility Criteria
Inclusion
- Primary diagnosis of major depressive disorder
- Male and female subjects, ages 22-65
- Have failed at least 1 antidepressant medication at adequate dose and duration
- On stable antidepressant medication regimen for at least 4 weeks prior to TMS therapy
Exclusion
- Diagnosed with a psychotic, bipolar, obsessive-compulsive or post-traumatic stress disorder
- Active substance abuse, including alcohol
- Medical and/or neurological condition that could affect your brain function or risk of seizure, including a stroke, epilepsy, or a closed head injury;
- No presence of an implanted device like a pacemaker/neurostimulator or metal in the head or body;
- Pregnant or trying to get pregnant
- Failed to respond to an adequate course of electroconvulsive therapy (ECT)
- Previous treatment with TMS
- Current depressive episode longer than 5 years
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01900314
Start Date
September 1 2013
End Date
April 1 2016
Last Update
April 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109